The analysis results of TIMER indicated that compared with normal tissues, IGFL1, the ligand of IGFLR1, was up-regulated in colon adenocarcinoma, lung adenocarcinoma, lung squamous cell carcinoma, rectum adenocarcinoma, THCA and uterine corpus endometrial carcinoma, while down-regulated in ccRCC and kidney renal papillary cell carcinoma (p < 0.05) (Supplementary Figure S2A). Here, IGFL1 is linked to nonpapillary renal cell carcinoma.